

This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damage arising from the translation.



May 28, 2026

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL: <https://www.modalistx.com/en/>

Representative: Haruhiko Morita

Modalis Therapeutics to Present New Preclinical Data for MDL-103 (FSHD) at the FSHD Society 2026 International Research Congress
— CRISPR-GNDM[®] epigenome editing shows potential as a therapeutic approach for FSHD —

TOKYO & WALTHAM, Mass., May 28, 2026 — Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a preclinical-stage biotechnology company developing precision gene therapies using its proprietary CRISPR-GNDM[®] epigenome editing technology, today announced that it will present new preclinical data for MDL-103, its program for facioscapulohumeral muscular dystrophy (FSHD), at the FSHD Society 2026 International Research Congress (IRC), taking place June 25–26, 2026 in Rosemont, Illinois.

The presentation will report preclinical data on epigenetic suppression of DUX4 using the Modalis's CRISPR-GNDM[®] technology. The poster is scheduled to be displayed during the poster session from 6:10 p.m. to 8:10 p.m. on June 25, 2026, and the program also includes a 5-minute oral presentation beginning at 2:40 p.m. and a 10-minute Q&A session on June 26, 2026.

Presentation Highlights

1. MDL-103 (Indication: FSHD)

MDL-103 leverages the Modalis's CRISPR-GNDM[®] technology to suppress expression of DUX4, the gene driving FSHD pathology, without cutting the DNA. The presentation will provide an overview of the epigenetic regulation approach targeting the D4Z4 repeat array in which DUX4 is located, including in vitro evaluation using myogenic cells derived from patients with FSHD, evaluation in 3D muscle tissue models, and in vivo evaluation in a mouse xenograft model transplanted with patient-derived muscle cells.

2. Key Presentation Points

- Suppression of DUX4 and its target genes confirmed in in vitro evaluation using myogenic cells derived from patients with FSHD
- Suppression of DUX4 and related target genes evaluated in 3D muscle tissue models
- Reduction in expression of DUX4 target genes reported following systemic administration of muscle-tropic AAV-CRISPR-GNDM[®] in an in vivo mouse xenograft model transplanted with patient-derived muscle cells
- Data on DUX4 target genes including KHDC1L, TRIM43, and ZSCAN4

- Evaluation results for myogenic markers MYOG, MYF6, MYH8, and DMD, together with off-target analysis results

Poster Presentation: [2026-IRC-Program-Outline-1.pdf](#)

Title: Epigenetic suppression of DUX4 using CRISPR-GNDM technology as a therapeutic for FSHD

Speaker: Alec M. DeSimone, PhD

Oral Presentation: June 26, 2026 (Day 2), 2:40 p.m., 5 minutes

Poster Session: June 25, 2026 (Day 1), 6:10 p.m. to 8:10 p.m.

About FSHD Society 2026 International Research Congress

The International Research Congress hosted by the FSHD Society is an international conference focused on facioscapulohumeral muscular dystrophy (FSHD). Researchers, clinicians, patient organizations, and industry participants gather to present and discuss a broad range of topics, including basic research, clinical research, biomarkers, and therapeutic development. In 2026, the congress is scheduled to be held in Rosemont, Illinois, from June 25 to 26 in a hybrid format combining in-person and online participation.

(<https://www.fshdsociety.org/research-and-clinical-care/for-researchers/international-research-congress/>)

About Modalis:

Modalis Therapeutics develops precision genetic medicines using epigenome editing technology. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM[®] technology, which enables gene- or locus-specific modulation of gene expression or epigenetic editing without the need for DNA cleavage or alteration of DNA sequence. Headquartered in Tokyo with laboratories and facilities in Waltham, Massachusetts, the company is listed on the Tokyo Stock Exchange Growth Market. For additional information, visit www.modalistx.com.

For media contacts

Modalis Therapeutics

Sawako Nakamura

media@modalistx.com